Pure Tango, Inc. – Trademark Portfolio

Entity Type: 03

Pure Tango, Inc. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include PRIAPLEX, ALLERPHASE, FEMMEPHASE, and OSTEOPHASE. The owner is based in San Francisco, CA.

2247 44th Avenue

San Francisco, CA 94116

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Pure Tango, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

Frequently Asked Questions

How many trademarks does Pure Tango, Inc. have?

Pure Tango, Inc. has 6 U.S. trademarks filed with the USPTO. Of these, 4 registered, 2 cancelled.

What trademark classes does Pure Tango, Inc. file in?

Pure Tango, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Pure Tango, Inc.'s most well-known trademarks?

Pure Tango, Inc.'s registered trademark portfolio includes well-known marks such as PRIAPLEX, ALLERPHASE, FEMMEPHASE, and OSTEOPHASE. These are among 4 currently registered trademarks in the portfolio.

What is Pure Tango, Inc.'s trademark registration success rate?

Pure Tango, Inc. has a 67% trademark registration rate, with 4 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.